TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17201251
Drug: Aildenafil citrate
Normalized name: Sildenafil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aildenafil citrate 30 or 60 mg
Study: 12562652
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (ciprofloxacin and roxithromycin)
Study: 19947900
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once daily
Study: 30304457
Drug: 8% micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% micronized vaginal progesterone (MVP) gel 90 mg daily
Study: 28265691
Drug: BMS-986142 (5-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986142 (5-900 mg single dose; 25-350 mg multiple doses, once daily for 14 days)
Study: 28265691
Drug: BMS-986142 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986142 (350 mg, once daily for 5 days)
Study: 16308253
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (200 microg/day) for 3 months
Study: 8819498
Drug: Buprenorphine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine maintenance (8 mg/day with p.o. placebo)
Study: 8819498
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance (80 mg/day)
Study: 3864038
Drug: Hyperimmune hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune hepatitis B immunoglobulin (HBIg) administered at birth and six weeks
Study: 29037773
Drug: S+NAC500 (simethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: S+NAC500 (simethicone 200 mg + N-acetylcysteine 500 mg)
Study: 29037773
Drug: S+NAC1000 (simethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: S+NAC1000 (simethicone 200 mg + N-acetylcysteine 1000 mg)
Study: 29037773
Drug: S (simethicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: S (simethicone 200 mg)
Study: 29037773
Drug: Water (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (100 mL)
Study: 16024862
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg intravenously before and after surgery, continued orally for 4 days at 20 mg/kg/8 hours)
Study: 29249583
Drug: Bronchial blocker
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial blocker (BB)
Study: 24231197
Drug: Bronchial blocker
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial blocker with disconnection technique (BB with disconnection)
Study: 20683173
Drug: Orlistat plus
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat plus L-carnitine (orlistat 120 mg three times a day plus L-carnitine 2 g one time a day)
Study: 20683173
Drug: Orlistat (orlistat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (orlistat 120 mg three times a day)
Study: 12594639
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (placebo)
Study: 7986714
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy with blood progenitor transplantation (priming regimen: cyclophosphamide 3 g/m2, etoposide 900 mg/m2 with GM-CSF; high-dose chemotherapy: thiotepa 750 mg/m2, busulfan 10 mg/kg, cyclophosphamide 120 mg/kg)
Study: 7986714
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients who did not receive intensive treatment
Study: 5090761
Drug: Slow-K (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-K (32 mEq daily)
Study: 5090761
Drug: Triamterene (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (50 mg twice daily)
Study: 26687696
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg SC every 2 weeks (Q2W)
Study: 26687696
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d (rechallenge)
Study: 18088263
Drug: Community nurse
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community nurse visits before discharge, within seven days of discharge, weekly for four weeks, then monthly.
Study: 10802159
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin injection therapy (CIT)
Study: 7684080
Drug: Seven pediculicidal
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven pediculicidal agents with their supplied nit removal combs
Study: 2949059
Drug: SKF 38393
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 38393 (selective D‐1 dopamine receptor agonist)
Study: 2949059
Drug: SKF 38393
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 38393 combined with intravenous levodopa
Study: 25614126
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (2 g)
Study: 23549137
Drug: Tonic treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonic treatment.
Study: 9433370
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 120 mg
Study: 16119039
Drug: Fexofenadine HCl
Normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine HCl 180 mg
Study: 2004528
Drug: Eutectic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic combination of EE:CHOL (50 mg of mixture providing 0.050 mg of ethinylestradiol)
Study: 2004528
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms tablet of ethinylestradiol (Dianor, Syntex)
Study: 2004528
Drug: Eutectic combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic combination of EE:CHOL
Study: 7047686
Drug: Azathioprine therapy
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine therapy (2 mg/kg/day)
Study: 31543215
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) as a periprocedural bridging anticoagulant
Study: 29936918
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (1.25 mg vitamin D3 monthly for 24 months)
Study: 25102730
Drug: Cytoflavin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytoflavin administration combined with standard therapy
Study: 24948702
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment
Study: 11789242
Drug: Salvia injection
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia injection and Di'ao Xinxuekang (Control)
Study: 29025406
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg/die
Study: 24029022
Drug: Ultrasound-guided combined
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided combined sciatic-femoral nerve block (USFB) with a 25 ml mixture (10 ml of 2.0% lidocaine, 10 ml of 0.5% levobupivacaine, and 5 ml of saline)
Study: 24029022
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anaesthesia (USA) with 2 ml (10 mg) of 0.5% levobupivacaine
Study: 19349078
Drug: Clomipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (mean dose 125 mg daily)
Study: 16700824
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (27.9±14.8 mg/kg/24 hr)
Study: 8384388
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin) 5,000 IU subcutaneously once daily for six days, starting preoperatively
Study: 27128496
Drug: Oxycodone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (1 mg/mL)
Study: 12884545
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg daily in pellets for 8 to 12 hours)
Study: 10871560
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g oat bran concentrate (OBC; containing 3 g beta-glucan)
Study: 10871560
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g wheat bran (control)
Study: 22508711
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg)
Study: 18846777
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg (single dose)
Study: 7555212
Drug: Best guess
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best guess combined antibiotic therapy (group COMB)
Study: 7555212
Drug: Open group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open group with free combination of antibiotics (group OPEN)
Study: 7072624
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron once daily
Study: 7072624
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron 3 times daily
Study: 29051325
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg every 4 weeks (2q4)
Study: 31917731
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept 2 mg every 12 weeks (2q12)
Study: 26731792
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg)
Study: 9693241
Drug: Piritramide (0.1‐0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramide (0.1‐0.3 mg/kg) and midazolam (1‐3 mg) i.v.
Study: 9693241
Drug: Lidocaine/prilocaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/prilocaine cream (30 g) topically and diclofenac suppository (100 mg)
Study: 7662079
Drug: Cefcanel 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefcanel 300 mg tablets twice daily
Study: 7662079
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg capsules three times daily
Study: 2547256
Drug: Prophylactic anti-CMV
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anti-CMV immunoglobulin administration
Study: 27669664
Drug: Chewed oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewed oxycodone DETERx
Study: 27669664
Drug: Intact oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact oxycodone DETERx
Study: 2828412
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (0.5 micrograms daily)
Study: 26563011
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (Control)
Study: 11801931
Drug: Dexamethasone (0.15-1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15-1.0 mg/kg; maximum dose 8-25 mg)
Study: 7694306
Drug: haloperidol 2‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol 2‐20 mg daily
Study: 3123607
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levodopa with deprenyl
Study: 18266548
Drug: Caffeine-containing supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing supplement (200 mg)
Study: 10890612
Drug: Gastric (G)
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric (G) feeding
Study: 30672178
Drug: Needle-knife therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-knife therapy combined with moxa stick pressure moxibustion
Study: 23822942
Drug: Endovenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovenous laser ablation (EVLA) with concurrent phlebectomies
Study: 18647300
Drug: Dapoxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine (30 mg and 60 mg combined)
Study: 3520177
Drug: Computerized feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized feedback on prescription charges
Study: 22536592
Drug: Lycopene gel
DrugBank: Lycopene (DB11231)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lycopene gel
Study: 19886920
Drug: Grass allergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergy immunotherapy tablet (AIT) - Graza (Phleum pratense 75,000 SQ‐T/2800 BAU; ALK, Denmark) for 3 years followed by 1 year follow-up
Study: 19886920
Drug: Grass allergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass allergy immunotherapy tablet (AIT) - Graza
Study: 12951650
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (60 IU, once daily)
Study: 8964890
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg DEX daily
Study: 3924981
Drug: Pseudomonic acid
Normalized name: Pseudomonic acid
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pseudomonic acid cream applied three times a day for 5 days
Study: 28264725
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT) using PiezoWave 2 shockwave system, administered three times per week for 3 weeks.
Study: 28264725
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment to the calf muscle bulk, administered three times per week for 3 weeks.
Study: 25243340
Drug: EP-101 (12.5-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-101 (12.5-400 μg)
Study: 12545257
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine sulfate
Study: 12545257
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.25% ropivacaine
Study: 12545257
Drug: Physiological NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological NaCl solution (placebo)
Study: 9506001
Drug: Azelastine HCl
Normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine HCl (4.4 mg every 12 hrs)
Study: 9506001
Drug: Azelastine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine with ketoconazole (200 mg every 12 hrs)
Study: 8476215
Drug: OK-432 intracutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 intracutaneous injection
Study: 30126672
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg) + Desmopressin (40 micrograms, 4 puffs)
Study: 30126672
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg) + Placebo
Study: 23290819
Drug: PPM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPM plus cisplatin (230 mg/m(2) + 60 mg/m(2))
Study: 26113503
Drug: 0.2 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/day fluocinolone acetonide (FAc) implant in cataract after implant (CAI) group
Study: 21113799
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of co-morbid drug abuse
Study: 12728089
Drug: Amoxicillin‐clavulanate (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate (45 mg/kg/d) for 7 days
Study: 8976822
Drug: Carboplatin 500
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 500 mg/m2
Study: 1546776
Drug: AIDS education
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIDS education with optional HIV antibody testing
Study: 25306750
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg/day in combination with metformin 2 g/day
Study: 25306750
Drug: Metformin 1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1.5-2 g/day
Study: 15805377
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution) administered intravenously before oral administration of glucose
Study: 11207036
Drug: OK-432 intratumoral
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: OK-432 intratumoral injection (10 KE) before surgery
Study: 11207036
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no OK-432 injection)
Study: 9562618
Drug: Heparin during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin during hemodialysis
Study: 30502851
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Carboxymaltose (FCM) - 1000mg IV infusion over 15 minutes
Study: 30502851
Drug: Oral Ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ferrous Sulphate - 325mg daily until delivery
Study: 27513339
Drug: Protandim® (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protandim® (1 pill a day for 90 days)
Study: 29618599
Drug: Atorvastatin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (both doses)
Study: 20051130
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SRT)
Study: 15943653
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of CBT and SRT (COMBINED)
Study: 15866398
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone 0.1% cream
Study: 11956506
Drug: SB 249417
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 249417 (humanized anti-factor IX antibody)
Study: 9457933
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 (100 microg/d)
Study: 7620000
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG; 750 mg/kg)
Study: 6370028
Drug: Flunitrazepam (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1-2 mg)
Study: 31148979
Drug: 20IU of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20IU of oxytocin infusion
Study: 29144240
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (music + sucrose)
Study: 25990055
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium 2 mg/d for 8 weeks
Study: 25990055
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium (both doses)
Study: 23857975
Drug: Chemotherapy before
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy before radiation (CT1) - three cycles of cisplatin and etoposide before radiation
Study: 23857975
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after radiation (RT1) - same chemotherapy regimen after radiation
Study: 16332659
Drug: Isoflavone-enriched cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-enriched cereal bars (50 mg/d)
Study: 11109512
Drug: felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine (10 mg)
Study: 18297254
Drug: cilazapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (5 mg)
Study: 7964942
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial floxuridine (FUDR) 0.30 mg/kg/d, leucovorin (LV) 15 mg/m2/d, dexamethasone (Dec) 20 mg total dose as a 14-day hepatic arterial infusion via an implantable pump alternating with 2 weeks of saline
Study: 2891368
Drug: Temelastine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temelastine 75 mg twice daily
Study: 8733993
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg twice daily
Study: 24554791
Drug: Multimodal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal exercise program (60-min class twice a week for 16 weeks)
Study: 21427067
Drug: Venlafaxine 50
Normalized name: venlafaxine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 50 mg 1 hour prior to oxaliplatin infusion and venlafaxine extended release 37.5 mg b.i.d. from day 2 to day 11
Study: 17470165
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil as needed
Study: 17470165
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine daily
Study: 17470165
Drug: Squeeze technique
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Squeeze technique daily
Study: 4072874
Drug: Quiniday, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quiniday, 1200 mg once daily
Study: 4072874
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate (Quinora, 300 mg four times daily)
Study: 4072874
Drug: Quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinidine sulfate (Quinidex Extentabs, 600 mg twice daily)
Study: 29880162
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg Dexamethasone IV drip
Study: 29880162
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg Dexamethasone subcutaneous injection